Cancer is one of the leading causes of death globally, second only to heart disease in the United States. Nearly 20 million new cancer cases and 10 million cancer-related deaths are reported annually worldwide. Cancer screening is crucial in early detection and intervention for various types of cancer, including colon, lung, cervical, breast, and prostate cancer. Detecting these cancers early through screening can significantly improve outcomes by delaying or halting disease progression, increasing cure rates, and significantly reducing morbidity and mortality. Screening for cancer is a form of secondary prevention aimed at reducing mortality rates without necessarily altering the incidence of the disease. By identifying premalignant lesions and intervening early in the carcinogenic process, screening can slow disease progression and facilitate early curative therapy when appropriate.Due to the significant lag time in malignant transformation, screening provides an opportunity to detect premalignant lesions, intervene in the carcinogenic process early, slow disease progression, and initiate early curative therapy when possible and appropriate. While certain screening methods, such as Pap smears for cervical cancer, have demonstrated success in reducing mortality rates in patients, others, such as prostate-specific antigen testing for prostate cancer, remain more controversial. This activity delves into the nuances of cancer screening, emphasizing methods such as Pap smears for cervical cancer and contentious approaches such as prostate-specific antigen testing for prostate cancer. This activity emphasizes collaboration among interprofessional healthcare providers and provides them with tools to enhance screening practices and knowledge to promptly and effectively detect premalignant lesions in the carcinogenic process.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/18799
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.5 hours
Nursing: 1.5 hours
Pharmacy: 1.5 hours - MOC Credit Details: ABS - 1.5 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.5 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABIM - 1.5 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.5 Point; Credit Type(s): Self-Assessment (ABS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Clinical Pathology, Complex General Surgical Oncology, General Surgery, Hospital Medicine, Internal Medicine, Medical Oncology